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BackgroundThe number of patients on second-line highly active antiretroviral
therapy (HAART) regimens is increasing in resource-limited settings. We describe
the outcomes after 24 months for patients on LPV/r-based second-line regimens
followed up by the ESTHER programme in Phnom Penh, Cambodia. Methods
Seventy patients who initiated second-line HAART regimens more than 24 months
earlier were included, and immuno-virological data analyzed. HIV RNA viral load
was determined by real-time RT-PCR. HIV-1 drug resistance was interpreted
according to the ANRS algorithm. Results Of the 70 patients, two were lost to follow
up, three died and 65 (92.8%) remained on second-line treatment after 24 months of
follow up (median duration of treatment: 27.4 months). At switch to second-line, the
median CD4 T cell count was 106 cells/mm3 and the median viral load was 4.7
Log10. Second-line regimens prescribed were ddI/3TC/LPV/r (65.7%), ddI/TDF/LPV/r
(10.0%), ddI/AZT/LPV/r (8.6%) and TDF/3TC/LPV/r (7.1%). The median CD4 T cell
gain was +258 cells/mm3 at 24 months (n = 63). After 24 months of follow up,
92.3% (60/65) of the patients presented undetectable viral loads, giving an overall
treatment success rate of 85.7% (CI: 75.6- 92.0) in intent-to-treat analysis.
Conclusions These data suggest that a LPV/r-based second-line regimen is
associated with a high rate of virological suppression and immune reconstitution
after 24 months of follow up in Cambodia.
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